Testosterone Regulation Takes a Sharp Turn

Why FDA’s December Panel Raises Red Flags

Regulatory Analysis

The FDA’s regulation of testosterone therapy has long been a model of cautious, evidence-based policymaking.

For more than a decade, the agency maintained a consistent position: testosterone was approved only for men with medically documented hypogonadism, its benefits for age-related low testosterone remained unproven, and early signals of cardiovascular risk warranted strict warnings and further study.

That framework held from 2014 through early 2025 – reinforced by mixed scientific literature, rising off-label use, and growing concerns about “Low T” clinics, anabolic steroid misuse, and unclear long-term safety data.

But the December 2025 FDA panel meeting marked a dramatic break from that history.

A Sudden Shift in Tone and Purpose

At the center of the discussion was the TRAVERSE trial, a large study mandated by FDA to evaluate cardiovascular risk. TRAVERSE concluded that testosterone therapy did not increase heart attack or stroke risk in appropriately selected men – an important reassurance for patients with true hypogonadism.

But the trial was explicit. Its findings should not be generalized to men with age-related declines in testosterone.

Despite this, the panel’s conclusions went far beyond what is justified by the data.

Panelists urged the FDA to broaden TRT indications to include any symptomatic man with low morning testosterone; remove longstanding warnings about prostate cancer risk; de-schedule testosterone from its current Schedule III controlled substance classification; frame low testosterone as a “public health issue” requiring routine screening for all men; and reduce regulatory barriers despite well-documented misuse in low-T clinics and anti-aging markets.

These recommendations stand in sharp contrast to a decade of FDA guidance and to the body of evidence supporting cautious prescribing.

When Evidence and Policy Diverge

The scientific record supports several recent regulatory changes – including the removal of the boxed warning for cardiovascular risk and the addition of class-wide blood pressure warnings. Those steps align with TRAVERSE and with independently conducted blood pressure studies.

But nothing in the available data supports routine testosterone screening for the general population, a broad prescription of TRT for age-related low T, removal from controlled-substance oversight, or minimizing concerns about misuse and dependency.

Equally concerning, the panel gave little attention to the realities of testosterone abuse, the safety issues surrounding non-traditional testosterone sources (including compounded products and DHEA), the rise of unregulated “men’s health” clinics, or the patterns of steroid dependency and cycling seen in younger men.

Instead, the panel leaned heavily on rhetoric about stigma, access, and men’s health advocacy – language more commonly seen in marketing than in regulatory science.

A Pattern Emerging Across Federal Health Agencies

This meeting did not occur in a vacuum. It follows a string of unusual regulatory moves under current FDA and HHS leadership, including proposed black-box warnings for COVID vaccines without transparent data; politicization of ACIP deliberations; weakening of long-standing vaccine evaluation processes; and decision-making that bypasses norms of advisory review and scientific transparency.

In this context, the December testosterone panel raises the same central concern: Are major regulatory decisions being driven by science or by policy agendas that predate the data?

What Is at Stake for Patients and for Public Trust

Testosterone deficiency is real, and for men with true hypogonadism, treatment can be life changing.

But expanding TRT into a mass-market therapy under relaxed controls carries risks, including cardiovascular implications from increased blood pressure, trends in overuse, and the possibility of opioid-style commercialization of a hormone with known abuse potential.

The public relies on the FDA to draw these boundaries carefully, transparently, and based on rigorous evidence.

The December meeting suggests those boundaries may now be shifting for reasons that extend beyond science.

Our Position

Our analysis is guided by a core regulatory principle. Scientific evidence must always precede regulatory change – not the other way around.

The FDA has a long history of cautious, disciplined regulation of testosterone therapy. That history should not be rewritten without full transparency of evidence, robust public discussion, independent advisory engagement, and acknowledgment of real-world risks.

We will continue monitoring these developments and will provide ongoing analysis as new information emerges – particularly if FDA moves to implement the far-reaching changes suggested by the December panel.

Links

A Decade of Drift – How U.S. Testosterone Regulation Reached a Crossroads